Dr. Franziska Michor   - CML  - Chronic myeloid leukemia

"Dr. Michor is a Professor of Computational Biology in the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cells and Regenerative Biology at Harvard University. Dr. Michor obtained her undergraduate training in mathematics and molecular biology from the University of Vienna, Austria, and her PhD from the Department of Organismic and Evolutionary Biology at Harvard University. Afterwards, she was awarded a fellowship from the Harvard Society of Fellows. From 2007 until 2010, she was an Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Michor is the director of the Dana-Farber Cancer Institute Physical Sciences-Oncology Center and the Center for Cancer Evolution. She has been the recipient of the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, the Alice Hamilton Award , the Vilcek Prize for Creative Promise in Biomedical Science, the 36th Annual AACR Award for Outstanding Achievement in Cancer Research, and others. Dr. Michor's laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance."
Extract from  Dana-Farber Cancer Institute
"Her quantitative approaches have called into question drug regimens for cancer treatments, in particular, chronic myelogenous leukemia (CML), a type of blood cell cancer. Dr. Michor used sophisticated mathematical models to trace the evolution of these blood cancer cells. Over time, cancer cells build up immunity to drug treatments since the cells that survive treatment divide to create larger treatment-resistant populations. Dr. Michor’s work simulates what happens if drugs are introduced in different time intervals in order to optimize treatment by reducing the amount of surviving cancer cells. "
Extract from   Franziska Michor receives New-York Stem Cell Foundation – Robertson Stem Cell Prize
PUBLICATIONS

Dynamics Of Chronic Myeloid Leukemia Response To Dasatinib, Nilotinib, And High-Dose Imatinib
November 2014, Haematologica
 
​Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. 
May 2007, Harvard – Department of Stem Cell and Regenerative  Biology
                                          Other Publications

                       See also Math could help cure chronic myeloid leukemia?
                        See also CML Experts in USA​
​